Drugs / Anti-hCD70 CAR transduced PBL
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02830724 | Apr 2017 → Jan 2029 expected | breast cancer, malignant pancreatic neoplasm, melanoma, ovarian cancer +1 | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-hCD70 CAR transduced PBL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02830724 ↗ |
| Modality | Cell therapy | “Transducing peripheral blood lymphocytes (PBL) with this CAR conveys major histocompatibility complex (MHC)-independent recognition of CD70-expressing target cells” NCT02830724 ↗ |
| Route | Intravenous | “Cells will be infused intravenously on the Patient Care Unit” NCT02830724 ↗ |
| Target | CD70 | “anti-hCD70 CAR-transduced PBL can mediate the regression of CD70 expressing tumors.” NCT02830724 ↗ |